Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q2 2026 · 10-Q
Revenue$227.63K$227.63K— vs Q2 2025 Net Income-$2.37M-$2.37MN/M vs Q2 2025 EPS Diluted-$4.46-$4.46N/M vs Q2 2025 Operating Income-$2,631,021N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-1155.8%
Net margin-1042.8%
ended Jun 30, 2026 · filed Aug 12, 2026 · 43 d after period end